The Medicines Company  

(Public, NASDAQ:MDCO)   Watch this stock  
Find more results for MDCO
35.59
-0.24 (-0.67%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.92 - 35.76
52 week 25.27 - 43.79
Open 35.50
Vol / Avg. 512,209.00/705,114.00
Mkt cap 2.48B
P/E     -
Div/yield     -
EPS -3.32
Shares 70.01M
Beta 0.63
Inst. own 122%
May 27, 2016
Medicines Co Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 26, 2016
Medicines Co Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 9, 2016
Q1 2016 Medicines Co Earnings Release - 9:30AM EDT - Add to calendar
May 9, 2016
Q1 2016 Medicines Co Earnings Call - 8:30AM EDT - Add to calendar
Mar 9, 2016
Medicines Co at Cowen Health Care Conference - Webcast
Feb 23, 2016
Medicines Co at RBC Capital Markets Healthcare Conference - Webcast
Feb 17, 2016
Q4 2015 Medicines Co Earnings Release
Feb 17, 2016
Q4 2015 Medicines Co Earnings Call - Webcast
Feb 10, 2016
Medicines Co at Leerink Partners Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -389.05% -71.82%
Operating margin -283.78% -86.56%
EBITD margin - -76.90%
Return on average assets -15.22% -12.02%
Return on average equity -34.90% -26.58%
Employees 614 -
CDP Score - -

Address

8 SYLVAN WAY
PARSIPPANY, NJ 07054
United States - Map
+1-973-2906000 (Phone)
+1-973-6569898 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company's products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

Officers and directors

Clive A. Meanwell Ph.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
William Bernard O'Connor Chief Financial Officer, Principal Accounting Officer
Age: 57
Bio & Compensation  - Reuters
Jeffrey Frazier Executive Vice President, Chief Human Strategy Officer
Age: 52
Bio & Compensation  - Reuters
Stephen M. Rodin J.D. Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Fredric N. Eshelman Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Elizabeth H.S. Wyatt Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Alexander J. Denner Ph.D. Director
Age: 46
Bio & Compensation  - Reuters
William W. Crouse Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert J. Hugin Independent Director
Age: 61
Bio & Compensation  - Reuters